Citadel Advisors LLC Buys Shares of 40,944 Edesa Biotech, Inc. (NASDAQ:EDSA)

Citadel Advisors LLC bought a new stake in Edesa Biotech, Inc. (NASDAQ:EDSA) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 40,944 shares of the company’s stock, valued at approximately $70,000.

Separately, Two Sigma Securities LLC bought a new stake in shares of Edesa Biotech during the 4th quarter valued at $26,000. Institutional investors own 5.50% of the company’s stock.

Edesa Biotech Stock Performance

NASDAQ:EDSA opened at $1.90 on Wednesday. Edesa Biotech, Inc. has a 52-week low of $1.55 and a 52-week high of $5.59. The firm has a market cap of $13.34 million, a price-to-earnings ratio of -1.02 and a beta of 0.41. The business’s fifty day moving average is $2.16 and its 200 day moving average is $2.12.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30). Equities analysts predict that Edesa Biotech, Inc. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Edesa Biotech in a research note on Thursday, March 13th.

Edesa Biotech Company Profile

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.